enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Global Partners LP (GLP) Upgraded to Buy: What Does It ... - AOL

    www.aol.com/news/global-partners-lp-glp-upgraded...

    Global Partners LP (GLP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  3. What Makes Global Partners LP (GLP) a Strong Momentum Stock ...

    www.aol.com/news/makes-global-partners-lp-glp...

    Need help? Call us! 800-290-4726 Login / Join. Mail

  4. Global Partners (GLP) Catches Eye: Stock Jumps 7.5% - AOL

    www.aol.com/news/global-partners-glp-catches-eye...

    Global Partners (GLP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  5. Global Partners - Wikipedia

    en.wikipedia.org/wiki/Global_Partners

    Global Partners LP (NYSE: GLP) is an American energy supply company ranked 361 in the 2018 Fortune 500. [3] The company is organized as a master limited partnership, and its operations focus on the importing of petroleum products and marketing them in North America. It wholesales products like crude oil, diesel oil, gasoline, heating oil and ...

  6. GLP (company) - Wikipedia

    en.wikipedia.org/wiki/GLP_(company)

    GLP was listed on the Singapore Exchange in October 2010, raising S$3.45 billion ($2.7 billion) in its initial public offering. [5] [13] Through a joint venture with GIC, China Investment Corporation and CPP Investment Board, GLP expanded to Latin America in 2012 by purchasing over 30 logistics assets in Brazil for $1.45 billion. [13]

  7. Is Global Partners LP (GLP) Stock Outpacing Its Oils-Energy ...

    www.aol.com/news/global-partners-lp-glp-stock...

    For premium support please call: 800-290-4726 more ways to reach us

  8. GLP1 poly-agonist peptides - Wikipedia

    en.wikipedia.org/wiki/GLP1_poly-agonist_peptides

    GLP1 poly-agonist peptides [1] are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor.These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease.

  9. Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is ...

    www.aol.com/eli-lilly-shares-fall-glp-111700194.html

    Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.